Skip to main content
Evidence Snapshot

Antithrombin-III

CHEMBL1950 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:50:56Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1950
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Antithrombin-III as ChEMBL target CHEMBL1950, mapped to UniProt P01008. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Antithrombin-III
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1950
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P01008
Antithrombin-III
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Antithrombin-III matters

As of 2026-09-13

Antithrombin-III is reviewed as Antithrombin-III (UniProt P01008); Antithrombin-III shows approved-linked disease relevance led by deep vein thrombosis. 5 more disease programs remain visible in the same review block.; 8 linked drugs keep this evidence frame grounded.; the current evidence base includes 0 approved drugs, 27 compounds, and 11 assays, with lead potency reaching pChEMBL 9.0.

Disease context
deep vein thrombosis

Antithrombin-III shows approved-linked disease relevance led by deep vein thrombosis. 5 more disease programs remain visible in the same review block. 8 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include BEMIPARIN SODIUM, DALTEPARIN SODIUM, ENOXAPARIN SODIUM.

Start review with deep vein thrombosis because it currently carries approved-linked support. Linked drugs include BEMIPARIN SODIUM, DALTEPARIN SODIUM, ENOXAPARIN SODIUM, FONDAPARINUX SODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 8 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 0 approved drugs, 27 compounds, and 11 assays for this target. The dominant activity type is IC50. CHEMBL5314374 is the current potency anchor at pChEMBL 9.0.

Use CHEMBL5314374 as the tractability anchor when discussing potency (pChEMBL 9.0).

Activity source · ChEMBL 36 via Core Engine
pChEMBL 9.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Antithrombin-III matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P01008, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why deep vein thrombosis is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

27
Total Compounds
11
Total Assays
0
Approved Drugs
IC50: 16.0, KD: 5.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL5314374
 9.0 Kd Clinical
No preferred name
CHEMBL2303815
 8.7 Kd —
No preferred name
CHEMBL2303814
 8.6 Kd —
No preferred name
CHEMBL1909451
 8.2 Kd —
No preferred name
CHEMBL609990
 7.2 Kd —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:50:56Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1950